Compounds > arsenic trioxide
Page last updated: 2024-08-21

arsenic trioxide and Kidney Neoplasms

arsenic trioxide has been researched along with Kidney Neoplasms in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (50.00)29.6817
2010's5 (41.67)24.3611
2020's1 (8.33)2.80

Authors

AuthorsStudies
Cai, LC; Cheng, SY; Jian, WG; Wang, TD; Wang, XY; Yang, JK; Yang, KB; Yu, YP; Zhang, C; Zhang, DM1
An, R; Gong, M; Gu, X; Guo, G; Han, K; Xu, Y1
Bandi, S; Dogra, S; Gupta, S; Viswanathan, P1
Arora, N; Das, R; Malhotra, P; Nath, A; Patel, FD; Varma, N; Varma, S1
Allegood, J; Cruickshanks, N; Curiel, DT; Dash, R; Dent, P; Dmitriev, IP; Fisher, PB; Grant, S; Hamed, HA; Mitchell, C; Ogretmen, B; Park, MA; Spiegel, S; Tye, G; Yacoub, A1
An, R; He, C; Su, Y; Wang, X; Xu, W; Xue, L; Yang, D1
Motzer, RJ; Schwartz, L; Vuky, J; Yu, R1
Hee Cho, Y; Hyuck Im, Y; Hyun Park, W; Ki Kang, W; Kim, K; Lee, MH; Oh Park, J; Park, K; Won Jung, C1
Brannon, J; Dent, P; Fisher, PB; Gopalkrishnan, RV; Grant, S; Lebedeva, IV; Linehan, WM; McKinstry, R; Mitchell, C; Qiao, L; Rosenberg, E; Sarkar, D; Su, ZS; Valerie, K; Yacoub, A1
Ahmed, M; Gazelle, GS; Goldberg, SN; Horkan, C; Kruskal, JB; Liu, Z; Solazzo, SA1
Kakehi, Y; Ogawa, O; Wu, XX1
Hampton, T1

Trials

1 trial(s) available for arsenic trioxide and Kidney Neoplasms

ArticleYear
Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma.
    Investigational new drugs, 2002, Volume: 20, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Karnofsky Performance Status; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Oxides; Tomography, X-Ray Computed

2002

Other Studies

11 other study(ies) available for arsenic trioxide and Kidney Neoplasms

ArticleYear
BMP8A promotes survival and drug resistance via Nrf2/TRIM24 signaling pathway in clear cell renal cell carcinoma.
    Cancer science, 2020, Volume: 111, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Bone Morphogenetic Proteins; Carcinoma, Renal Cell; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Male; Mice; Mice, Nude; NF-E2-Related Factor 2; Prognosis; Reactive Oxygen Species; Wnt Signaling Pathway

2020
Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment.
    Cancer biology & therapy, 2013, Oct-01, Volume: 14, Issue:10

    Topics: Annexin A7; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Galectin 3; Gene Knockdown Techniques; Humans; Kidney Neoplasms; Membrane Potential, Mitochondrial; Oxides; Pectins; Protein Transport; RNA, Small Interfering

2013
Arsenic trioxide amplifies cisplatin toxicity in human tubular cells transformed by HPV-16 E6/E7 for further therapeutic directions in renal cell carcinoma.
    Cancer letters, 2015, Jan-28, Volume: 356, Issue:2 Pt B

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Ataxia Telangiectasia Mutated Proteins; Blotting, Western; Carcinoma, Renal Cell; Cell Cycle; Cell Proliferation; Cell Transformation, Viral; Cisplatin; Comet Assay; DNA Breaks, Double-Stranded; Drug Synergism; Histones; Human papillomavirus 16; Humans; Kidney Neoplasms; Kidney Tubules; Oncogene Proteins, Viral; Oxides; Papillomavirus E7 Proteins; Papillomavirus Infections; Promoter Regions, Genetic; Repressor Proteins; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2015
Treatment of therapy related acute promyelocytic leukemia with the combination of all trans retinoic acid and arsenic trioxide without chemotherapy: a series of three patients.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Choriocarcinoma; Female; Humans; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neuroectodermal Tumors; Ovarian Neoplasms; Oxides; Prognosis; Tretinoin

2010
A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels.
    Molecular pharmacology, 2011, Volume: 79, Issue:3

    Topics: Adenoviridae; Animals; Arsenic Trioxide; Arsenicals; Benzoquinones; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Ceramides; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Female; Flow Cytometry; Humans; Interleukins; Kidney Neoplasms; Lactams, Macrocyclic; Mice; Mice, Nude; Oxides; Reactive Oxygen Species; Transfection

2011
Arsenic trioxide increases the sensitivity of 786-0 renal carcinoma cells to radiotherapy.
    Cancer investigation, 2012, Volume: 30, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Renal Cell; Cell Line, Tumor; DNA Damage; G2 Phase Cell Cycle Checkpoints; Humans; Kidney Neoplasms; M Phase Cell Cycle Checkpoints; Membrane Potential, Mitochondrial; Oxides; Radiation-Sensitizing Agents; Reactive Oxygen Species

2012
Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis.
    Biochemical and biophysical research communications, 2003, Jan-03, Volume: 300, Issue:1

    Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Carcinoma, Renal Cell; Caspases; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cyclin A; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Humans; Kidney Neoplasms; Oxides; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Retinoblastoma Protein; Tumor Cells, Cultured

2003
MDA-7 (interleukin-24) inhibits the proliferation of renal carcinoma cells and interacts with free radicals to promote cell death and loss of reproductive capacity.
    Molecular cancer therapeutics, 2003, Volume: 2, Issue:7

    Topics: Acetylcysteine; Adenoviridae; Adjuvants, Immunologic; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Brain Neoplasms; Carcinoma, Renal Cell; Caspases; Cell Division; Free Radical Scavengers; Free Radicals; Genes, Tumor Suppressor; Glioma; Glutathione Transferase; Humans; Interleukins; Kidney; Kidney Neoplasms; Oxides; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Receptors, Virus; Recombinant Fusion Proteins; Tumor Cells, Cultured

2003
Radiofrequency ablation: Effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model.
    Journal of vascular and interventional radiology : JVIR, 2004, Volume: 15, Issue:3

    Topics: Adrenergic Agonists; Anesthetics, Inhalation; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carcinoma; Catheter Ablation; Disease Models, Animal; Epinephrine; Halothane; Kidney; Kidney Neoplasms; Laser-Doppler Flowmetry; Liver; Liver Neoplasms; Oxides; Rabbits; Regional Blood Flow

2004
Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
    International journal of oncology, 2004, Volume: 24, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Carcinoma, Renal Cell; Caspases; Cell Division; Doxorubicin; Drug Synergism; Fluorouracil; Glutathione; Glutathione Transferase; Humans; Kidney Neoplasms; Oxidation-Reduction; Oxides; Tumor Cells, Cultured; Vinblastine

2004
Cancer agents show first-line potential.
    JAMA, 2007, Jul-25, Volume: 298, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bevacizumab; Dasatinib; Humans; Kidney Neoplasms; Leukemia; Oxides; Pyrimidines; Thiazoles

2007